Salhab A S, Edwards G S
Cancer Res. 1977 Apr;37(4):1016-21.
The metabolism of [14C]aflatoxicol by liver postmitochondrial and microsomal fractions from humans and eight other species was compared. A major metabolic pathway involves the dehydrogenation of aflatoxicol yielding aflatoxin B1. Human liver preparations were more active in this regard than preparations from any of the other species tested. The aflatoxicol dehydrogenase activity was mainly associated with the microsomal fraction and required a hydrogen acceptor (e.g., nicotinamide adenine dinucleotide phosphate), but was not inhibited by carbon monoxide, which implies that it was not dependent on the heme-containing microsomal drug-metabolizing system. It had a pH optimum of 8.0. Postmitochondrial liver fractions also oxidized aflatoxicol (and/or the aflatoxin B1 made from it) to at least five other metabolites that comigrated on thin-layer chromatography plates with authentic standards of aflatoxins Q1,P1,H1,M1, and B2a. None of these oxidative metabolites were formed in the presence of carbon monoxide. We also report on the in vitro reduction of aflatoxin B1 to aflatoxicol by the cytosol fractions from eight species. Most active in this regard were rabbit and trout preparations, while this activity was almost absent in the guinea pig. Preparations from humans and four other species were intermediate between these extremes.
比较了来自人类和其他八个物种的肝脏线粒体后和微粒体部分对[14C]黄曲霉毒素醇的代谢情况。一条主要的代谢途径涉及黄曲霉毒素醇脱氢生成黄曲霉毒素B1。在这方面,人类肝脏制剂比所测试的任何其他物种的制剂都更具活性。黄曲霉毒素醇脱氢酶活性主要与微粒体部分相关,需要氢受体(如烟酰胺腺嘌呤二核苷酸磷酸),但不受一氧化碳抑制,这表明它不依赖于含血红素的微粒体药物代谢系统。其最适pH为8.0。线粒体后肝脏部分也将黄曲霉毒素醇(和/或由其生成的黄曲霉毒素B1)氧化为至少其他五种代谢产物,这些代谢产物在薄层色谱板上与黄曲霉毒素Q1、P1、H1、M1和B2a的标准品共迁移。在一氧化碳存在的情况下,这些氧化代谢产物均未形成。我们还报告了来自八个物种的细胞溶质部分将黄曲霉毒素B1体外还原为黄曲霉毒素醇的情况。在这方面最具活性的是兔和鳟鱼制剂,而豚鼠制剂几乎没有这种活性。人类和其他四个物种的制剂活性介于这两个极端之间。